Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Pregnancy and breast cancer: a population-based study.

Reed W, Hannisdal E, Skovlund E, Thoresen S, Lilleng P, Nesland JM.

Virchows Arch. 2003 Jul;443(1):44-50. Epub 2003 May 20.

PMID:
12756565
2.
4.

Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.

Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris AC, Tzonou A, Keramopoulos A.

J Pathol. 1996 May;179(1):31-8.

PMID:
8691341
5.

Over-expression of c-erbB-2 correlates with nuclear morphometry and prognosis in breast carcinoma in Asian women.

Selvarajan S, Wong KY, Khoo KS, Bay BH, Tan PH.

Pathology. 2006 Dec;38(6):528-33.

PMID:
17393979
6.

C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre.

Sharifah NA, Lee BR, Clarence-Ko CH, Tan GC, Shiran MS, Naqiyah I, Rohaizak M, Fuad I, Tamil AM.

Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):663-70.

7.

Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options.

Gentilini O, Masullo M, Rotmensz N, Peccatori F, Mazzarol G, Smeets A, Simsek S, De Dosso S, Veronesi P, Intra M, Zurrida S, Viale G, Goldhirsch A, Veronesi U.

Eur J Surg Oncol. 2005 Apr;31(3):232-6.

PMID:
15780556
8.

Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.

Francis G, Beadle G, Thomas S, Mengersen K, Stein S.

Pathology. 2006 Oct;38(5):391-8.

PMID:
17008275
9.

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.

10.
11.

Clinicopathologic characteristics and prognosis of breast cancer patients associated with pregnancy and lactation: analysis of case-control study in Japan.

Ishida T, Yokoe T, Kasumi F, Sakamoto G, Makita M, Tominaga T, Simozuma K, Enomoto K, Fujiwara K, Nanasawa T, et al.

Jpn J Cancer Res. 1992 Nov;83(11):1143-9.

PMID:
1483929
12.

Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.

Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T.

Breast Cancer. 2010 Apr;17(2):118-24. doi: 10.1007/s12282-009-0113-0. Epub 2009 May 23.

PMID:
19466512
13.

Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.

Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, Fernö M, Parwaresch R, Alm P.

J Pathol. 1999 Jan;187(2):207-16.

PMID:
10365096
14.

Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.

Gaci Z, Bouin-Pineau MH, Gaci M, Daban A, Ingrand P, Métayé T.

Int J Oncol. 2001 Apr;18(4):793-800.

PMID:
11251176
15.
16.

Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates.

Miyashita M, Ishida T, Ishida K, Tamaki K, Amari M, Watanabe M, Ohuchi N, Sasano H.

Virchows Arch. 2011 Jan;458(1):65-72. doi: 10.1007/s00428-010-1009-2. Epub 2010 Nov 21.

PMID:
21104095
17.
18.

Breast cancer in young women: prognostic factors and clinicopathological features.

Aryandono T, Harijadi, Soeripto.

Asian Pac J Cancer Prev. 2006 Jul-Sep;7(3):451-4.

19.

LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.

Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.

Anticancer Res. 2004 Jul-Aug;24(4):2391-400.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk